• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

当代经皮冠状动脉介入治疗中生物可吸收支架的应用及技术要点:欧洲视角。

Contemporary practice and technical aspects in coronary intervention with bioresorbable scaffolds: a European perspective.

机构信息

Ferrarotto Hospital, University of Catania, Catania, Italy.

出版信息

EuroIntervention. 2015 May;11(1):45-52. doi: 10.4244/EIJY15M01_05.

DOI:10.4244/EIJY15M01_05
PMID:25599676
Abstract

AIMS

Next to patient characteristics, the lack of a standardised approach for bioresorbable vascular scaffold (BVS) implantation is perceived as a potential explanation for the heterogeneous results reported so far. To provide some guidance, we sought to find a consensus on the best practices for BVS implantation and management across a broad array of patient and lesion scenarios.

METHODS AND RESULTS

Fourteen European centres with a high volume of BVS procedures combined their efforts in an informal collaboration. To get the most objective snapshot of different practices among the participating centres, a survey with 45 multiple choice questions was prepared and conducted. The results of the survey represented a basis for the technical advice provided in the document, whereas areas of controversy are highlighted.

CONCLUSIONS

Consensus criteria for patient and lesion selection, BVS implantation and optimisation, use of intravascular imaging guidance, approach to multiple patient and lesion scenarios, and management of complications, were identified.

摘要

目的

除了患者特征外,生物可吸收血管支架(BVS)植入缺乏标准化方法,这被认为是迄今为止报告的结果存在异质性的一个潜在原因。为了提供一些指导,我们试图就广泛的患者和病变情况下 BVS 植入和管理的最佳实践达成共识。

方法和结果

14 家欧洲中心拥有大量的 BVS 手术经验,它们在一次非正式合作中联合起来。为了更客观地了解参与中心之间的不同实践,我们准备并进行了一项包含 45 个多项选择题的调查。该调查的结果为文件中提供的技术建议提供了依据,同时突出了存在争议的领域。

结论

确定了患者和病变选择、BVS 植入和优化、血管内成像指导的使用、多种患者和病变情况的处理方法以及并发症管理的共识标准。

相似文献

1
Contemporary practice and technical aspects in coronary intervention with bioresorbable scaffolds: a European perspective.当代经皮冠状动脉介入治疗中生物可吸收支架的应用及技术要点:欧洲视角。
EuroIntervention. 2015 May;11(1):45-52. doi: 10.4244/EIJY15M01_05.
2
Bioresorbable Stents: Is This Where We Are Headed?生物可吸收支架:我们正朝着这个方向发展吗?
Prog Cardiovasc Dis. 2015 Nov-Dec;58(3):342-55. doi: 10.1016/j.pcad.2015.08.011. Epub 2015 Aug 28.
3
Significant differences between vascular and nonvascular surgeons in the perioperative management of antiplatelet therapies in patients with coronary stents.血管外科医生和非血管外科医生在冠状动脉支架置入患者抗血小板治疗围手术期管理方面存在显著差异。
Ann Vasc Surg. 2015 Apr;29(3):526-33.e2. doi: 10.1016/j.avsg.2014.09.031. Epub 2014 Dec 1.
4
The future of bioresorbable vascular scaffolds: niche or workhorse devices?生物可吸收血管支架的未来:小众产品还是主流器械?
Coron Artery Dis. 2017 Sep;28(6):449-451. doi: 10.1097/MCA.0000000000000513.
5
Anatomical features and management of bioresorbable vascular scaffolds failure: A case series from the GHOST registry.生物可吸收血管支架失败的解剖学特征与处理:来自GHOST注册研究的病例系列
Catheter Cardiovasc Interv. 2015 Jun;85(7):1150-61. doi: 10.1002/ccd.25819. Epub 2015 Feb 12.
6
New insights on acute expansion and longitudinal elongation of bioresorbable vascular scaffolds in vivo and at bench test: a note of caution on reliance to compliance charts and nominal length.生物可吸收血管支架在体内和台架试验中的急性扩张和纵向伸长的新见解:对依赖顺应性图表和标称长度的警示
Catheter Cardiovasc Interv. 2015 Mar;85(4):E99-E107. doi: 10.1002/ccd.25645. Epub 2014 Sep 3.
7
Percutaneous coronary intervention with everolimus-eluting bioresorbable vascular scaffolds in routine clinical practice: early and midterm outcomes from the European multicentre GHOST-EU registry.依维莫司洗脱生物可吸收血管支架在常规临床实践中的经皮冠状动脉介入治疗:欧洲多中心GHOST-EU注册研究的早期和中期结果
EuroIntervention. 2015 Feb;10(10):1144-53. doi: 10.4244/EIJY14M07_11.
8
Bioresorbable vascular scaffold implantation for recurrent in-stent restenosis: an option in case of multiple failures?生物可吸收血管支架植入治疗复发性支架内再狭窄:多次治疗失败时的一种选择?
EuroIntervention. 2014 Jul;10(3):337. doi: 10.4244/EIJV10I3A57.
9
Current practice of transradial approach for coronary procedures: A survey by the Italian Society of Interventional Cardiology (SICI-GISE) and the Italian Radial Club.冠状动脉介入手术经桡动脉途径的当前实践:意大利介入心脏病学会(SICI-GISE)和意大利桡动脉俱乐部的一项调查。
Cardiovasc Revasc Med. 2017 Apr-May;18(3):154-159. doi: 10.1016/j.carrev.2017.01.005. Epub 2017 Jan 17.
10
Incidence and imaging outcomes of acute scaffold disruption and late structural discontinuity after implantation of the absorb Everolimus-Eluting fully bioresorbable vascular scaffold: optical coherence tomography assessment in the ABSORB cohort B Trial (A Clinical Evaluation of the Bioabsorbable Everolimus Eluting Coronary Stent System in the Treatment of Patients With De Novo Native Coronary Artery Lesions).植入可吸收依维莫司洗脱完全生物可吸收血管支架后急性支架断裂和晚期结构不连续性的发生率和影像学结果:ABSORB 队列 B 试验的光学相干断层成像评估(生物可吸收依维莫司洗脱冠状动脉支架系统治疗初发原生冠状动脉病变患者的临床评价)。
JACC Cardiovasc Interv. 2014 Dec;7(12):1400-11. doi: 10.1016/j.jcin.2014.06.016.

引用本文的文献

1
Bioresorbable Scaffolds for Below-the-Knee Arterial Disease: A Literature Review of New Developments.用于膝下动脉疾病的生物可吸收支架:新进展的文献综述
Rev Cardiovasc Med. 2024 Apr 3;25(4):133. doi: 10.31083/j.rcm2504133. eCollection 2024 Apr.
2
Two-Year Outcomes for Patients with Non-ST-Elevation Acute Coronary Syndrome Treated with Magmaris and Absorb Bioresorbable Scaffolds in Large-Vessel Lesions.使用Magmaris和Absorb生物可吸收支架治疗大血管病变的非ST段抬高型急性冠状动脉综合征患者的两年结局
J Pers Med. 2024 May 17;14(5):540. doi: 10.3390/jpm14050540.
3
Bioresorbable Magnesium-Based Stent: Real-World Clinical Experience and Feasibility of Follow-Up by Coronary Computed Tomography: A New Window to Look at New Scaffolds.
生物可吸收镁基支架:真实世界临床经验及冠状动脉计算机断层扫描随访的可行性:观察新型支架的新窗口
Biomedicines. 2023 Apr 11;11(4):1150. doi: 10.3390/biomedicines11041150.
4
Outcomes of the two generations of bioresorbable scaffolds (Magmaris vs. Absorb) in acute coronary syndrome in routine clinical practice.两代生物可吸收支架(Magmaris与Absorb)在急性冠状动脉综合征常规临床实践中的结果。
Cardiol J. 2022 May 27;30(6):870-80. doi: 10.5603/CJ.a2022.0047.
5
Long-Term Outcomes After Implantation of Magnesium-Based Bioresorbable Scaffolds-Insights From an All-Comer Registry.镁基生物可吸收支架植入后的长期预后——来自全人群注册研究的见解
Front Cardiovasc Med. 2022 Apr 14;9:856930. doi: 10.3389/fcvm.2022.856930. eCollection 2022.
6
Clinical presentation does not affect acute mechanical performance of the Novolimus-eluting bioresorbable vascular scaffold as assessed by optical coherence tomography.通过光学相干断层扫描评估,临床表现不影响诺华莫司洗脱生物可吸收血管支架的急性机械性能。
Postepy Kardiol Interwencyjnej. 2021 Sep;17(3):272-280. doi: 10.5114/aic.2021.109239. Epub 2021 Sep 20.
7
Stent Selection for Primary Angioplasty and Outcomes in the Era of Potent Antiplatelets. Data from the Multicenter Randomized Prague-18 Trial.强效抗血小板时代的直接经皮冠状动脉腔内血管成形术支架选择及预后。来自多中心随机布拉格-18试验的数据。
J Clin Med. 2021 Oct 30;10(21):5103. doi: 10.3390/jcm10215103.
8
Long-term outcomes after treatment of in-stent restenosis using the Absorb everolimus-eluting bioresorbable scaffold.采用 Absorb 依维莫司洗脱生物可吸收支架治疗支架内再狭窄的长期结果。
Open Heart. 2021 Sep;8(2). doi: 10.1136/openhrt-2021-001776.
9
Final report of the 5-year clinical outcomes of the XINSORB bioresorbable sirolimus-eluting scaffold in the treatment of single coronary lesions in a first-in-human study.XINSORB生物可吸收西罗莫司洗脱支架治疗单支冠状动脉病变的首次人体研究5年临床结果的最终报告。
Ann Transl Med. 2020 Sep;8(18):1162. doi: 10.21037/atm-20-5668.
10
Three-year outcomes of bioresorbable vascular scaffolds versus second-generation drug-eluting stents: Meta-analysis of randomized trials.生物可吸收血管支架与第二代药物洗脱支架的三年疗效:随机试验的荟萃分析
Medicine (Baltimore). 2020 Jul 31;99(31):e21554. doi: 10.1097/MD.0000000000021554.